$IBIO SEC Filings

Filed On	Filing
19 Oct 2026	8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year +1 more 1.He is the Chief Executive Officer and Chief Scientific Officer of iBio, Inc. (the “Corporation”), a Delaware corporation, and is duly authorized by the Board of Directors of the Corporation to execute this instrument.
15 Oct 2026	Form 4: Stoner Elizabeth, Director Granted 38,000 Stock Option (right to buy)
15 Oct 2026	Form 4: Kropotova Alexandra, Director Granted 38,000 Stock Option (right to buy)
15 Oct 2026	Form 4: Arkowitz David, Director Granted 38,000 Stock Option (right to buy)
15 Oct 2026	Form 4: Clark William D, Director Granted 38,000 Stock Option (right to buy)
15 Oct 2026	Form 4: Parada Antonio Bernardino Guimaraes, Director Granted 38,000 Stock Option (right to buy)
15 Oct 2026	Form 4: Sender Gary, Director Granted 38,000 Stock Option (right to buy)
14 Oct 2026	SCHEDULE 13G
13 Oct 2026	8-K: Regulation FD Disclosure; Other Events iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy
14 Sep 2026	8-K: Regulation FD Disclosure; Other Events BREAKTHROUGH ANTIBODIES FOR OBESITY AND CARDIOMETABOLIC DISEASES CORPORATE PRESENTATION • September 2026
04 Sep 2026	ARS
04 Sep 2026	Proxy statement: annual meeting on October 14, 2026 CEO pay $2.1M, up 42% · say-on-pay vote
28 Aug 2026	10-K
28 Aug 2026	8-K: Results of Operations and Financial Condition
20 Aug 2026	PRE 14A
14 Aug 2026	SCHEDULE 13G
14 Aug 2026	SCHEDULE 13G/A
14 Aug 2026	SCHEDULE 13G/A
13 Aug 2026	SCHEDULE 13G/A
04 Aug 2026	Form 4: Carr Molly, Chief Medical Officer Granted 430,000 Stock Option (right to buy)

Comments